VeraBank N.A. Sells 436 Shares of Amgen, Inc. (NASDAQ:AMGN)

VeraBank N.A. trimmed its holdings in Amgen, Inc. (NASDAQ:AMGN) by 6.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,099 shares of the medical research company’s stock after selling 436 shares during the quarter. VeraBank N.A.’s holdings in Amgen were worth $1,180,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. BlackRock Inc. raised its stake in shares of Amgen by 3.4% in the second quarter. BlackRock Inc. now owns 47,717,316 shares of the medical research company’s stock valued at $8,793,346,000 after purchasing an additional 1,585,911 shares in the last quarter. Morgan Stanley raised its stake in shares of Amgen by 0.5% in the second quarter. Morgan Stanley now owns 6,753,145 shares of the medical research company’s stock valued at $1,244,470,000 after purchasing an additional 34,674 shares in the last quarter. Nuveen Asset Management LLC raised its stake in shares of Amgen by 1,334.9% in the second quarter. Nuveen Asset Management LLC now owns 4,942,807 shares of the medical research company’s stock valued at $910,860,000 after purchasing an additional 4,598,329 shares in the last quarter. Nordea Investment Management AB raised its stake in shares of Amgen by 5.0% in the first quarter. Nordea Investment Management AB now owns 4,709,467 shares of the medical research company’s stock valued at $894,700,000 after purchasing an additional 225,485 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Amgen by 9.4% in the second quarter. Price T Rowe Associates Inc. MD now owns 2,780,461 shares of the medical research company’s stock valued at $512,383,000 after purchasing an additional 239,576 shares in the last quarter. 76.24% of the stock is owned by institutional investors.

In other news, Director R Sanders Williams sold 425 shares of the firm’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $183.04, for a total value of $77,792.00. Following the completion of the sale, the director now directly owns 16,336 shares in the company, valued at $2,990,141.44. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Cynthia M. Patton sold 13,426 shares of the firm’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $208.07, for a total value of $2,793,547.82. Following the completion of the sale, the senior vice president now owns 32,648 shares of the company’s stock, valued at $6,793,069.36. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 17,851 shares of company stock valued at $3,671,900. 0.25% of the stock is currently owned by corporate insiders.

A number of research analysts recently commented on AMGN shares. Cowen set a $231.00 target price on Amgen and gave the company a “buy” rating in a research note on Sunday, September 29th. Royal Bank of Canada restated a “hold” rating on shares of Amgen in a research note on Monday, September 30th. William Blair reiterated a “hold” rating on shares of Amgen in a research note on Friday, August 30th. Credit Suisse Group reiterated an “outperform” rating and set a $225.00 price objective (up from $202.00) on shares of Amgen in a research note on Friday, August 16th. Finally, JPMorgan Chase & Co. reiterated a “hold” rating on shares of Amgen in a research note on Monday, September 30th. Eleven equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $217.41.

Amgen stock traded up $4.13 during mid-day trading on Friday, hitting $202.81. 1,430,181 shares of the company were exchanged, compared to its average volume of 2,465,687. The company has a quick ratio of 2.60, a current ratio of 2.89 and a debt-to-equity ratio of 2.58. The business has a fifty day moving average of $199.57 and a 200 day moving average of $186.20. Amgen, Inc. has a 1-year low of $166.30 and a 1-year high of $211.90. The company has a market capitalization of $117.59 billion, a PE ratio of 14.08, a price-to-earnings-growth ratio of 2.55 and a beta of 1.11.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, July 30th. The medical research company reported $3.97 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.58 by $0.39. Amgen had a return on equity of 76.17% and a net margin of 33.78%. The company had revenue of $5.87 billion during the quarter, compared to analyst estimates of $5.67 billion. During the same period last year, the company posted $3.83 earnings per share. The firm’s quarterly revenue was down 3.1% compared to the same quarter last year. Research analysts expect that Amgen, Inc. will post 14.31 earnings per share for the current year.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Featured Story: How to Track your Portfolio in Google Finance

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.